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OBJECTIVE—Type 1 diabetes is an incurable chronic autoim-
mune disease. Although transplantation of pancreatic islets may
serve as a surrogate source of insulin, recipients are subjected to
a life of immunosuppression. Interleukin (IL)-21 is necessary for
type 1 diabetes in NOD mice. We examined the efﬁcacy of an IL-
21–targeted therapy on prevention of diabetes in NOD mice, in
combination with syngeneic islet transplantation. In addition, we
assessed the role of IL-21 responsiveness in islet allograft rejec-
tion in mouse animal models.
RESEARCH DESIGN AND METHODS—NOD mice were
treated with IL-21R/Fc, an IL-21–neutralizing chimeric protein.
This procedure was combined with syngeneic islet transplanta-
tion to treat diabetic NOD mice. Survival of allogeneic islet grafts
in IL-21R–deﬁcient mice was also assessed.
RESULTS—Evidence is provided that IL-21 is continually re-
quired by the autoimmune inﬁltrate, such that insulitis was reduced
and reversed and diabetes inhibited by neutralization of IL-21 at
a late preclinical stage. Recovery from autoimmune diabetes was
achieved by combining neutralization of IL-21 with islet trans-
plantation. Furthermore, IL-21–responsiveness by CD8+ T-cells
was sufﬁcient to mediate islet allograft rejection.
CONCLUSIONS—Neutralization of IL-21 in NOD mice can
inhibit diabetes, and when paired with islet transplantation, this
therapeutic approach restored normoglycemia. The inﬂuence of
IL-21 on a graft-mounted immune response was robust, since the
absence of IL-21 signaling prevented islet allograft rejection.
These ﬁndings suggest that therapeutic manipulation of IL-21 may
serve as a suitable treatment for patients with type 1 diabetes.
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n type 1 diabetes, activated immune cells lead to the
destruction of the insulin-producing b-cells in the
islets of Langerhans of the pancreas (1). Clinical
diabetes occurs in the nonobese diabetic (NOD)
model after months of chronic pancreatic inﬂammation,
progressing from peri-insulitis to destructive insulitis (2,3).
Importantly, therapies designed to modulate lymphocyte
activation are compatible with the prevention of the de-
structive form of insulitis, i.e., the movement of immune
cells into the islet, and subsequent loss of insulin pro-
duction from b-cells (4,5).
Insulin replacement is the current standard for treating
type 1 diabetes, however, transplantation of pancreatic
islets has the potential to serve as a viable alternative (6).
Challenges of islet transplantation include ﬁnding alter-
natives to broad-spectrum immunosuppression (7) while
preventing graft rejection and recurrence of the underlying
autoimmune destruction of pancreatic islets. As T-cells
constitute an integral component in both autoimmune
responses of diabetes and the rejection of transplanted
islet allografts (8,9), therapies addressing modulation of
T-cell function may provide an appropriate strategy.
IL-21 is a member of the common g-chain signaling family
of cytokines that is necessary for the development of di-
abetes in the NOD mouse (10–12). The receptor for IL-21,
comprising the a unit (IL-21Ra) and the common g chain, is
expressed on immune cells including T-, B-, NK, and den-
dritic cells, whereas IL-21 expression is largely limited to
CD4+ T-cells (13). Several studies demonstrate that IL-21
acts as a lymphocyte costimulator, enhancing the prolif-
eration and effector function of CD8+ T-cells (14,15), and
transgenic over-expression of murine IL-21 revealed that IL-21
predominantly expands memory phenotype CD8+ T-cells
(16). The prosurvival effect of IL-21 is important for CD8+
T-cells during chronic viral infection (17–19), with IL-21 also
potently effecting the activation and differentiation of nu-
merous CD4+ T-helper subsets, including Th17 cells (20,21).
Consistent with its actions on lymphocyte populations,
IL-21 has been found to contribute to the development of
autoimmune diseases in several animal models (22).
Likewise, IL-21 has the potential to inﬂuence the outcome
of islet graft transplantation (23–25). For instance, IL-21
has a well-documented ability to promote the production
of granzyme and perforin in differentiating CD8+ cytotoxic
T-cells. Direct killing of islet cells by antigen-speciﬁc cy-
totoxic T-cells is an important component of both allograft
rejection and the autoimmune destruction of b-cells (26,27).
Secondly, IL-21 costimulates the activation and differen-
tiation of antigen speciﬁc CD4+ T-cells, and these cells
can produce proinﬂammatory cytokines that are toxic to
the islets, such as IL-1b, tumor necrosis factor-a,a n d
g-interferon (IFNg)( 2 8 –31).
In this study, we demonstrate that IL-21 acts on immune
cells to elicit autoimmune destruction of endogenous
pancreatic islet tissue in autoimmune diabetes and islet
graft rejection caused by both autoimmune and allogeneic
immune responses. We provide evidence that through the
modulation of IL-21, a potential therapeutic intervention
for type 1 diabetes may be attainable.
RESEARCH DESIGN AND METHODS
NOD Ltj, C57BL/6, and BALB/c mice were obtained from Animal Resources
Centre, Perth. NOD/Scid mice were obtained from Walter and Eliza Hall
Institute of Medical Research, Melbourne. The Il21
2/2 mice were created
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the 129 background and backcrossed to C57BL/6. These mice were back-
crossed to NOD N10 and selected for known NOD Idd loci (vs. B6 regions) by
PCR of genomic DNA (speed congenics), as previously described (32). Il21r
2/2
mice (33) were kindly provided by M. Smyth (Melbourne) at C57BL/6 N6 and
backcrossed to N7 for experimental use; both Il21r
2/2 and Il21
2/2 NOD mice
underwent an additional genome scan of +600 NOD microsatellite markers.
Major histocompatibility complex (MHC) class II–deﬁcient mice (stock 3584,
Jackson Laboratories) were kindly provided by R. Brink (Sydney). Animals
were housed under speciﬁc pathogen-free conditions and handled in accor-
dance with the Garvan Institute of Medical Research and St. Vincent Hospital’s
Animal Experimentation and Ethics Committee. Blood glucose levels were
determined using Accu-chek Advantage blood glucose strips (Roche).
In vivo IL-21 neutralization. IL-21R/Fc chimera was generated in-house, as
previously described (34). In brief, the DNA encoding the predicted extra-
cellular domain (aa 1–235) of mouse IL-21R with a GSGS linker were ampliﬁed
by PCR, and linked to mIgG2a Fc. The Fc domain contains four amino acid
mutations (L285E, E368A, K370A, and K372A) to minimize Fc binding and
complement ﬁxation (34). The resulting construct was subcloned into pEE12.4
(Lonza), a mammalian glutamine synthase expression vector, transfected into
Chinese hamster ovary-K1SV cells, and grown in the presence of 25 mmol/L
methionine sulphoximine. Following protein A puriﬁcation, purity of IL-21R/Fc
was checked by SDS/PAGE (Coomassie blue staining and silver stain, Lonza)
(Supplementary Fig. 1) and tested for presence of endotoxin (Lonza). In vitro
BAF-3 proliferation assay measuring biological activity of IL-21R/Fc construct
was conducted as previously described (35) (Supplementary Fig. 1).
Complete treatment of NOD mice consisted of a total of 20 mg IL-21R/Fc
given every other day for 11 days. Flow cytometric analyses were conducted
at time points relative to this treatment regimen. Treatment of NOD transplant
recipients consisted of a total of 80 mg IL-21R/Fc given on day 21, day 0, and
every other day until day 12. A monoclonal Ig control was provided with
a nonspeciﬁc antibody (afﬁnity puriﬁed, produced in house). Mice received
60 mg polyclonal IL-21 antibody (goat IgG; R&D Systems) as an alternative
IL-21 neutralizing reagent. The frequency of diabetes was compared between
treatment groups with the Kaplan-Meier log-rank test using Prism software
(GraphPad).
Immunohistochemistry. Parafﬁn-embeddedsectionsofpancreasandengrafted
kidney were conventionally stained with hematoxylin and eosin or insulin by
immunocytochemical techniques. For insulitis scoring, serial sections of pan-
creata were matched and stained for insulin (DakoCytomation) and glucagon
(Chemicon). For islet mass scoring, sections of pancreata were stained for in-
sulin. Images were processed using the Leica acquisition and analysis software
ImageJ (Freeware; National Institutes of Health, Bethesda, MD).
Flow-cytometric analysis. We stained lymphocytes extracted from the
pancreasand pancreaticlymph nodeswithconjugatedantibodies toAnnexin V,
B220, CD4, CD8, CD45 (BD Biosciences), and CD11b, CD11c, CD44, CD69,
Foxp3, and IL-17 (eBioscience). For ﬂow-cytometric analysis of lymphocytes
isolated from the pancreas, mice were killed by intraperitoneal injection of
ketamine and perfused with ice-cold PBS for 10 min. Pancreas samples were
then subjected to lymphocyte isolation as described (36). For IL-21 analysis,
after ex vivo staining of surface markers, cells were ﬁxed and permeated (BD
Biosciences), followed by intracellular staining with biotin labeled polyclonal
IL-21 Ab (R&D Systems). For IL-17 analysis, cells were stimulated with CD3
(2.5 mg/mL) and CD28 mAb (2.5 mg/mL) in culture medium containing monensin
(GolgiStop 1 mL/mL; BD Biosciences) at 37°C for 6 h. Intracellular staining
was performed according to the manufacturer’s instructions, for IL-17 (BD
Biosciences) and Foxp3 (eBioscience). Data were collected on a Canto ﬂow
cytometer (BD Biosciences), and analyzed using FlowJo software (Tree
Star).
RNA and quantitative RT-PCR. Total RNA was harvested from tissues or
cells using TRIzol (Invitrogen). Pancreas samples were perfused through the
bile duct with RNAlater (Ambion). Tail vein bleeds were collected into
RNAlater. Preparation of complementary DNA and analysis of IL-21 gene ex-
pression was performed with Taqman gene expression assays (Applied Bio-
systems) as described previously, with values normalized to the level of
expression of the housekeeping gene GAPDH (37).
Islet transplantation. Autoimmune diabetic NOD mice received islets pre-
pared from NOD/Scid mice (forsyngeneic transplants), and chemically induced
diabetic mice (C57BL/6 and Il21r
2/2 mice, H-2
b), injected with 180 mg/kg
streptozotocin (Sigma-Aldrich), received islets prepared from BALB/c (H-2
d)
(for allogeneic transplants). Islets were prepared as described previously (38).
Statistical analysis. We used an F test to compare variances, and when
variances were signiﬁcantly different t tests were performed with Welch
correction (without assuming equal variances). P values between datasets
were determined by two-tailed Student t test assuming equal variance, with
log-rank test used in Figs. 1B, D,a n dG,4 A,5 A,a n d6 A. Data are reported as
the mean 6 SEM, along with the calculated P values.
RESULTS
Islet inﬂammation is chronically dependent on IL-21.
We have shown previously that NOD mice express higher
levels of IL-21 compared with diabetes-resistant strains
(37,39). NOD mice made genetically deﬁcient for IL-21R
lack insulitis and do not develop diabetes (10–12). We used
an IL-21R/Fc chimeric protein to therapeutically neutralize
IL-21 at different periods of time in the disease process. IL-
21 was neutralized from 7 to 9 weeks of age in one group,
and IL-21 was neutralized from 14 to 16 weeks of age in
another group. We also compared groups treated with IL-
21R/Fc with NOD mice made genetically deﬁcient in IL-21
that do not develop insulitis (Fig. 1A) or diabetes during
the 40 week observation period (Fig. 1B).
Histological analysis of pancreata 5 weeks after treat-
ment of 7-week-old mice revealed islets with mild peri-
insulitis, but very few islets exhibited insulitis compared
with control mice (Fig. 1C). However, this early short-term
treatment was reversible and ultimately had little impact
on diabetes incidence (Fig. 1D). The 11 day neutralization
of IL-21 in mice treated on the brink of clinical diabetes
(14-weeks-of-age) also reduced insulitis in the pancreatic
islets compared with control mice (Fig. 1E). Because NOD
islets at the start of treatment exhibited a considerably
greater degree of insulitis than those at the end of treat-
ment, our results indicate that insulitis was reversed
whether we treated with the IL-21R/Fc chimera or an IL-21
neutralizing polyclonal antibody (Fig. 1F). Furthermore, in
contrast to the 7-week-old group, the effect of the 11 day
treatment was not reversible in mice treated at a late
preclinical stage, delaying the onset and reducing the in-
cidence of diabetes to 40%, compared with 90% of control
mice by 40 weeks of age (Fig. 1G). These ﬁndings indicate
that IL-21 was required for the transition from peri-insulitis
to insulitis.
Neutralization of IL-21 reduced lymphocytes in the
islet lesion. To further examine the reduction of inﬂam-
mation caused by neutralization of IL-21, we investigated the
effect of IL-21 neutralization on the islet inﬁltrate from the
start of treatment (day 0) and up to 12-weeks after treatment
(day 90). One of the early effects of treatment (day 5) was to
reduce the percentages and total numbers of lymphocytes in
the islet inﬁltrate comprising CD4+ T-cells, CD8+ T-cells, and
B220+ B-cells (Fig. 2A and B, and Supplementary Fig. 2).
Analyses of the long-term effects of IL-21 neutralization
showed the sustained reduction in CD8+ T-cells and B-cells,
but not CD4+ T-cells, 90 days after treatment (Fig. 2A and B,
and Supplementary Fig. 2). The percentage of macro-
phages and dendritic cells were proportionally increased,
however, absolute numbers of both subsets remained
largely unchanged (Fig. 2C and D, and Supplementary
Fig. 2).
Analyses of cell surface molecules that distinguish acti-
vated T-cells from naïve T-cells indicated that IL-21 neu-
tralization preferentially reduced the number of activated
lymphocytes in the islet inﬁltrate (Table 1). The reduction of
CD44
hi CD8+ T-cells preceded that of CD4+ T-cells and B-
cells (data not shown) and was also sustained until 90 days
after treatment (Fig. 2E and F, and Supplementary Fig. 2).
IL-21 neutralization resulted in a profound reduction
in IL-21 expression (Fig. 2G) and IL-21–producing cells
(Fig. 2H and I) in the islets. The population of IL-21+ cells
had signiﬁcantly declined after treatment and remained
decreased in mice that had not developed diabetes by
40 weeks of age (Fig. 2I). By contrast, mice that did go on
to develop diabetes were distinguished from those who
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IL-21–producing CD4+ T-cells in the islet inﬁltrate (Fig. 2I).
Measuring IL-21 transcript in secondary lymphoid organs,
blood, and the pancreas over the course of disease in the
NOD mouse demonstrated that an increase in IL-21 in the
blood and pancreas corresponded with the age of height-
ened destruction of the islets and coincided with the onset
of diabetes in our colony (Supplementary Fig. 3). More-
over, the analyses of IL-21 mRNA in blood demonstrated
that high IL-21 expression was predictive of the sub-
sequent development of clinical diabetes (Fig. 2J).
The generation and survival of several TH subsets, in-
cluding T follicular helper cells (40), TH17 cells and TH2
cells (20,21), are inﬂuenced by IL-21. The analyses of
FIG. 1. IL-21 helps to maintain pancreatic immune cell inﬁltrate. A: Sections from parafﬁn-embedded pancreata were stained with hematoxylin and
eosin to reveal mononuclear inﬁltrate in and around islets of 15-week-old WT NOD and Il21
2/2 NOD mice, with cumulative incidence of diabetes in
WT NOD and Il21
2/2 NOD mice (B), where n = 12 mice per group. C: Sections from parafﬁn-embedded pancreata from NOD mice treated at 7 weeks
of age with a total of 20 mg control antibody or IL-21R/Fc, given every other day for 11 days are shown at 5 weeks after completion of treatment,
with cumulative incidence of diabetes (D), where n = 7 mice per group. Arrows indicate beginning and end of treatment period. E: Sections from
parafﬁn-embedded pancreata from NOD mice treated at 14 weeks of age with a total of 20 mg control antibody or IL-21R/Fc, given every other day
for 11 days are shown at 1 week after completion of treatment, with insulitis indices from sections of pancreata showing the percent of islets
exhibiting peri-insulitis or insulitis in 12-week-old, 17-week-old, and 22-week-old control mice, and 17-week-old mice treated with IL-21R/Fc or
IL-21 polyclonal antibody (1 week after completion of treatment) and 22-week-old mice treated with IL-21R/Fc (6 weeks after completion of
treatment) (F), n ‡ 220 islets from 10 mice per group. G: Cumulative incidence of diabetes in NOD mice commencing treatment at 14 weeks of age,
where n = 13 mice per group. Arrows indicate beginning and end of treatment period. w, week; WT, wild type. (A high-quality digital representation
of this ﬁgure is available in the online issue.)
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diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 869FIG. 2. IL-21 neutralization reduces lymphocyte populations. NOD mice were treated with IL-21R/Fc or control antibody 2.8 mg/i.v. every other day,
with a complete dosing of 20 mg achieved on day 11. Cellular composition of PBS-perfused pancreas preparations, and pancreatic lymph nodes were
examined by ﬂow cytometric analysis at time points relative to the start of treatment. A: Representative dot plots of CD4+ T-cells, CD8+ T-cells
(CD3+ CD45+ gating), and B220+ cells (CD45+ gating) in the pancreas on day 5 (receiving three doses of 2.8 mg). Numbers represent percentage of
total lymphocytes. B: Absolute cell number of CD4+ T-cells, CD8+ T-cells, and B220+ cells in the pancreas and pancreatic lymph nodes on day 5 and
day 90 (receiving full 20-mg dose) of treatment with IL-21R/Fc. C: Representative dot plots of CD11b and CD11c staining (CD45+ gating) in the
pancreas of IL-21R/Fc–treated mice, day 5. D: Absolute cell number of CD11b+ CD11c- macrophages and CD11b+ CD11c+ dendritic cells in NOD
pancreas, measured on day 5 of treatment with IL-21R/Fc. Data are presented as means 6 SEM, where n =5 –14 for each group, compiled from four
experiments. Representative dot plot (E) and absolute cell number of CD44
hi CD8+ T-cells from the pancreata of control and IL-21R/Fc–treated
NOD mice (F). G: IL-21 mRNA expression measured in pancreas of age-matched control and treated mice on day 3 of treatment with IL-21R/Fc, and
NOD mice remaining diabetes free at 40 weeks, termed nonprogressors, where n =4 –5 for each group, from two experiments. IL-21–expressing
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TH17 cells that were signiﬁcantly diminished during IL-
21R/Fc treatment (Fig. 3A and B). However, a greater than
50% reduction in the fraction of TH17 cells early in the
treatment regimen was consistent with an overall loss of
activated CD4+ T-cells rather than a speciﬁc effect on
TH17 cells. By contrast, there was no speciﬁc decline or
retention of Foxp3+ regulatory T-cells in either the pan-
creatic lymph nodes or pancreas (Fig. 3C and D).
Effective combination therapy with IL-21R/Fc and
pancreatic islet transplantation. These data show the
merit of neutralizing IL-21 at a late preclinical stage. To be
of relevance to human patients with type 1 diabetes, how-
ever, it would be more beneﬁcial to reverse diabetes once it
is clinically revealed, yet treatment of newly diabetic NOD
mice (15–20 weeks of age) with IL-21R/Fc failed to reverse
diabetes (data not shown).
Given the slow regeneration of the depleted b-cell mass
(41), we assessed whether IL-21 neutralization combined
with pancreatic islet transplantation could be a solution.
Newly diabetic NOD mice (with two consecutive blood
glucose readings above 18 mmol/L) were treated with IL-
21R/Fc (10 mg/IV) on day 21, day 0, and every other day
until day 12. Pancreatic islets from MHC-matched, lym-
phocyte deﬁcient NOD/Scid mice were grafted under the
kidney capsule of NOD mice (day 0). In mice treated with
IL-21R/Fc, destruction of the graft and subsequent diabetes
was delayed and reduced (Fig. 4A). The majority of treated
mice maintained a stable normal range of blood glucose
while undergoing treatment (Fig. 4B) with three of seven
mice returning to hyperglycemia, compared with the entire
untreated group with a mean survival time of 16.1 days.
To determine whether the graft was still necessary in
long-term (100 days) diabetes-free IL-21R/Fc–treated NOD
mice, islet grafted kidneys were removed in these mice
and blood glucose was measured. No considerable mod-
ulation of blood glucose level was observed after the
nephrectomy, and mice remained diabetes free for an-
other 100 days (Fig. 4C). This ﬁnding raised the possi-
bility that IL-21R/Fc treatment had affected the residual
endogenous islets, either by increasing islet mass or re-
storing function. Assessment of islet mass from histo-
logical sections of pancreata immunostained for insulin
indicated that IL-21R/Fc–treated NOD mice had equiva-
lent islet mass to that of 15–20-week-old diabetic NOD
mice, which were both signiﬁcantly reduced compared with
prediabetic NOD mice (Fig. 4D). Taken together these data
indicated that NOD pancreatic islets had regained func-
tionality through the combined effects of IL-21 neutralization
and transplantation of syngeneic islets and were capable of
maintaining normoglycemia without the islet graft.
Histological analysis of islet grafts from IL-21R/Fc–treated
long-term survivors revealed healthy insulin producing grafts
free from mononuclear cell inﬁltration (Fig. 4E). Further-
more, the pancreas revealed islet mass with mild peri-
insulitis (Fig. 4F). These ﬁndings showed that IL-21R/Fc
TABLE 1
Loss of activated lymphocytes in the pancreas following IL21R/Fc treatment
CD4+ T-cells
CD69+ CD44+
Percent Number Percent Number
Day 0 22.1 6 1.1 37,715 6 1,916 51.8 6 3.3 90,100 6 5,159
Day 5
Control 22.3 6 1.3 38,150 6 209 52.3 6 4.1 89,080 6 5,100
IL-21R/Fc 14.2 6 1.0 10,682 6 800 41.2 6 3.1 30,967 6 2,372
P 0.0014 ,0.0001 0.0198 ,0.0001
Day 90
Control 24.2 6 1.7 42,198 6 2,416 66.0 6 3.1 15,0810 6 5,672
IL-21R/Fc 18.2 6 0.7 31,000 6 1,326 51.8 6 8.2 88,100 6 14,061
P 0.0128 0.0036 0.0423 0.0033
CD8+ T-cells
CD69+ CD44+
Percent Number Percent Number
Day 0 24.8 6 1.7 23,564 6 937 60.1 6 4.9 62,250 6 6,029
Day 5
Control 26.7 6 2.0 24,760 6 1,447 62.9 6 5.7 59,210 6 9,313
IL-21R/Fc 15.7 6 1.6 7,879 6 718 45.6 6 4.7 19,090 6 2,934
P 0.0026 ,0.0001 0.070 0.0034
Day 90
Control 26.8 6 1.4 24,365 6 856 70.8 6 3.6 93,650 6 4,428
IL-21R/Fc 16.7 6 0.9 12,909 6 465 47.7 6 2.6 33,260 6 6,709
P 0.0003 ,0.0001 0.0052 0.0001
Percentage and absolute number of activated CD4+ and CD8+ T-cell subsets in NOD pancreas, measured on day 5 and day 90 of treatment
with IL-21R/Fc, relative to age-matched control antibody-treated NOD mice. n =5 –9 mice per group, from four experiments.
cells shown as representative dot plots (H) (CD4+ CD3+ CD45+ gating) day 5, and as a percentage of CD4+ T-cells (I), measured in pancreas of
control mice and mice on days of treatment with IL-21R/Fc shown, also compared with NOD mice remaining diabetes free at 35 weeks, termed
nonprogressors, and diabetic NOD mice, aged 14–22 weeks, where n =5 –10 for each group, from four experiments. J: IL-21 mRNA expression
measured by real-time PCR in blood from 12-week-old NOD mice. The cohort were monitored for diabetes onset until 40 weeks of age, and grouped
into those that developed disease (progressor) or nonprogressors.
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these data demonstrate that combining islet transplantation
(as a source of insulin) with speciﬁc immunomodulation of
IL-21 could reverse diabetes.
IL-21 inﬂuences allograft survival. These exciting ﬁnd-
ings have potential application for human type 1 diabetic
patients, however this circumstance would have the addi-
tional challenge of allograft rejection. Given this challenge,
we assessed the role of IL-21 in an islet allograft immune
response. A fully mismatched H-2
d BALB/c islet allograft
was transplanted into H-2
b wild type C57BL/6 (WT) and
H-2
b Il21r
2/2 streptozotocin-induced diabetic recipients.
All C57BL/6 (H-2
b) mice rejected the (H-2
d) islet allo-
graft with a mean survival time of day 16.6 (n = 8). In
comparison, 66% of Il21r
2/2 (H-2
b) mice failed to acutely
reject their H-2
d islet allografts (Fig. 5A). As indicated by
the individual blood glucose readings (Fig. 5B), the mice
that survived long-term consistently maintained steady
normoglycemic levels. Nephrectomies were performed on
100 day surviving Il21r
2/2 mice, resulting in loss of normo-
glycemia, conﬁrming that the islet allograft was functional
and responsible for controlling blood glucose in these mice.
In order to address whether lacking IL-21 responsive-
ness and an inability to reject the islet allograft was due to
a problem in immune priming capacity, we rechallenged
the nephrectomized mice with another H-2
d BALB/c islet
allograft, on the contralateral kidney. These secondary islet
allografts remained unchallenged, surviving a further
100 days (Fig. 5C). Histological analyses of the long-term
surviving islet allograft in Il21r
2/2 mice revealed strong
insulin production with very mild mononuclear cell in-
ﬁltrate peripheral to the graft (Fig. 5D). Taken together,
these results indicated that responsiveness to IL-21 was
crucial for successful rejection of islet allografts.
CD8 T-cell responsiveness to IL-21 is crucial to
allograft rejection. Given the important role IL-21 has
in CD8+ T-cell survival and effector function (16,42), and
the well documented critical role CD8+ T-cells have in the
rejection of pancreatic islet allografts (43), we determined
whether IL-21 responsiveness in CD8+ T-cells alone was
sufﬁcient to induce allograft rejection. The number and
activation status of CD8+ T-cells are not impaired in rest-
ing unchallenged Il21r
2/2 mice (14,33). However, in the
absence of IL-21 responsiveness, CD8+ T-cells become
“exhausted” in chronic viral infections, exhibiting “im-
paired self-maintenance” (17–19).
To address whether IL-21 responsiveness in CD8+ T-cells
was sufﬁcient to provoke islet allograft rejection, we
adoptively transferred IL-21R–sufﬁcient CD8+ T-cells into
Il21r
2/2 recipient mice and repeated the H-2
d BALB/c
islet allograft. We used MHC class II deﬁcient mice as the
source of CD8+ T-cells, thus eliminating the possibility of
contaminating CD4+ T-cells. As is shown in Fig. 6, restoring
IL-21 signaling to CD8+ T-cells alone resulted in rapid re-
jection of the allograft.
DISCUSSION
Cytokines can play both destructive and immunomodula-
tory roles in graft rejection. Roles for cytokines such as
IFNg, IL-1b, and tumor necrosis factor-a in allograft re-
jection have previously been described (44), but this study
is the ﬁrst to demonstrate a role for IL-21 in islet allograft
rejection. IL-21 was important for islet targeted autoimmune
inﬂammation in diabetes, and both autoimmune and allo-
graft responses against islet grafts. Pharmacological neu-
tralization of IL-21 at a late preclinical stage inhibited
insulitis and delayed diabetes. Moreover, IL-21 neutraliza-
tion when combined with syngeneic islet transplantation
reversed diabetes. It has previously been shown that di-
abetic NOD mice retain some islet mass (45,46). Removal of
the syngeneic islet graft from long-term (100 days) diabetes-
free IL-21R/Fc–treated NOD mice revealed that the residual
endogenous pancreatic islets (from previously clinically
diabetic NOD mice) had regained functionality and were
FIG. 3. IL-21 neutralization modulates activated TH subsets. IL-17–expressing cells shown as representative dot plots (A) and quantiﬁed in the
pancreas of treated vs. control mice on day 3 of treatment with IL-21R/Fc (B), as percentage of CD45+ cells, where n = 12 per group compiled from
ﬁve experiments. Absolute number of Foxp3+ CD25+ CD4+ T-cells in pancreatic lymph node on days of treatment with IL-21R/Fc shown (C), and in
pancreas on day 60 after treatment with IL-21R/Fc (D). Data are presented as means 6 SEM, where n = 5 per group from two experiments.
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islet graft.
Short-term neutralization of IL-21 reset the clock of au-
toimmune inﬁltration in mice on the brink of clinical dis-
ease indicating that the treatment both inhibits the ongoing
accumulation of inﬁltrating immune cells as well as af-
fecting resident lymphocytes, which emphasizes the dy-
namic nature of the islet lesion. Modulation of IL-21 for
the brief time period suggests that the autoimmune in-
ﬂammation is continually reliant on IL-21. The numbers of
IL-21–producing cells in the pancreatic lesion were in-
creased at the preclinical stage and were reduced by
neutralization of IL-21. An autocrine role for IL-21 on the
survival of IL-21–producing CD4+ T-cells has been dem-
onstrated previously and might offer an explanation as to
why the relatively short neutralization treatment regimen
could perpetuate a sustained effect at a preclinical stage.
In an effort to explore the therapeutic effect of IL-21
neutralization on islet inﬂammation, we analyzed the en-
dogenous pancreatic islet inﬁltrate and observed an im-
mediate reduction in the number of activated lymphocytes.
In particular, a sustained reduction in activated/memory-
phenotype CD8+ T-cells was observed. Indeed, there was
an approximately threefold decline in CD8+ T-cells 90 days
following short-term treatment, which indicates that this
population was less capable of recovering from treatment
than CD4+ T-cells or B-cells. CD8+ T-cells have a well-
supported role in both the early stage of disease, and in the
ﬁnal effector stage of diabetes (47,48). The broad effect of
IL-21 neutralization on lymphocytes in the islet lesion
probably reﬂects that IL-21 is produced by activated CD4+
T-helper cells and, as well as acting in an autocrine fash-
ion, provides soluble help by facilitating the differentiation
and survival of B cells and CD8+ cytotoxic T lymphocytes
(33,49,50). Furthermore, our ﬁndings suggest that mea-
surement of IL-21 could be a predictive marker for diabetes.
The inﬂuence of IL-21 on B-cells and T-cells indicates
possible roles in both cellular and humoral rejection. How-
ever, IL-21 responsiveness by CD8+ T-cells alone could re-
store islet allograft destruction. This ﬁnding provides insight
into the important clinical problem of organ allograft re-
jection, suggesting a potential role for IL-21 neutralization
combined with pancreatic islet grafts for patients with
type 1 diabetes. Interestingly, elevated IL-21 and IL-21R
mRNA have been shown in biopsies from cardiac allo-
graft recipients, with the highest mRNA expression levels
found in rejection specimens (51). These reports support
our ﬁnding that biological activities of the IL-21 pathway
contribute to the graft rejection process.
It remains to be shown in our study how IL-21 promotes
destruction of islet allografts by CD8+ T-cells. It is likely
that IL-21–mediated rescue from ‘exhaustion’ of the graft
speciﬁc CD8+ T-cells occurs, by a similar mechanism to
that observed in chronic viral infections (17–19). Our
ﬁnding of a role for IL-21 responsiveness in allograft re-
jection is in line with previous studies, which found that
loss of IL-21 signaling attenuated the pathogenesis of CD4+
T-cell mediated graft versus host disease (GVHD) (23–25).
Although these studies vary in the detail of their ﬁndings,
FIG. 4. IL-21 neutralization prolongs survival of autoimmune diabetic
mice. A: Percent diabetes-free NOD mice after syngeneic islet trans-
plants with IL-21R/Fc, with treatment period indicated on the graph. n =
10 for control NOD group, no treatment, mean survival time 16.1 days.
n = 7 for treated NOD group, three of seven mice returned to a diabetic
state. P=0.0002 (log-rank test). B: Individual blood glucose readings
are shown for a cohort of untreated and IL-21R/Fc–treated mice.
Treatment period is indicated on the graphs. C: Individual blood glu-
cose readings are shown for long-term surviving IL-21R/Fc–treated
NOD mice (n = 3) after nephrectomy (indicated by arrow). D: Fre-
quency of islet mass area in pancreas of long-term IL-21R/Fc–treated
NOD syngeneic graft recipients compared with 10-week-old C57BL/6
and prediabetic (preD) NOD mice, and newly diabetic (Diab) NOD mice
(15–17 weeks of age). Enumerated from histological sections, with at
least 50 ﬁelds scored, from three mice per group. Representative his-
tological analyses of a long-term surviving islet graft (E) and pancreas
(F) from a long-term surviving IL-21R/Fc–treated NOD mouse. (A high-
quality digital representation of this ﬁgure is available in the online
issue.)
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(24,25). Even though the majority of Il21r
2/2 mice ac-
cepted islet allografts long-term, these studies indicate
a degree of redundancy in the IL-21–IL-21R network, an
outcome that can be further explored with combined
therapies.
Studies collectively demonstrate that a variety of im-
munomodulatory reagents can protect the NOD mouse
from diabetes. However, there are few examples of re-
agents that can reverse insulitis (52,53) and only one other
reagent, namely anti-CD3 monoclonal antibody (54), that
has been shown to prevent the progress of type 1 diabetes
once blood glucose levels have begun to rise, leading to
clinical trials for type 1 diabetes (55). In contrast to anti-
CD3 treatment, neutralization of IL-21 did not reverse
disease in overtly diabetic NOD mice (52). However, in
accordance with anti-CD3 treatment, syngeneic islets
could be transplanted without recurrence of disease or
continuous administration of IL-21R/Fc. These inﬂuential
studies place the blockade of IL-21:IL-21R interactions in
an elite group of immunomodulatory agents in type 1 di-
abetes. The ability of short-term blockade of a single cy-
tokine to have such a profound effect on islet inﬂammation
is unprecedented and raises possibilities for intervention
in type 1 diabetes at a late preclinical stage and for the
protection of both allogeneic islet graft tissue and trans-
planted islet tissue during recurrent autoimmunity.
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